Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Impact of Genetic Mutations on the Efficacy of Immunotherapies in Lung Cancer.

International journal of molecular sciences - 7 Nov 2024

Lui Ki, Cheung Kwok-Kuen, Ng Winnie Wing-Man, Wang Yanping, Au Doreen W H, Cho William C

Abstract excerpt

Lung cancer is the leading cause of cancer-related mortality worldwide, primarily driven by genetic mutations. The most common genetic alterations implicated in lung cancer include mutations in TP53, KRAS, KEAP1, NF1, EGFR, NRF2, ATM, ALK, Rb1, BRAF, MET, and ERBB2. Targeted therapies have been developed to inhibit cancer growth by focusing on these specific genetic mutations. However, either the mutations are...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Cancer Immunotherapy and Biomarkers

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immune Checkpoint Inhibitors

Share to Immunotherapy

Share to Lung Cancer Treatments and Mutations

Share to Lung Neoplasms

Share to Molecular Targeted Therapy

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 39596025
DOI: 10.3390/ijms252211954
PMCID: PMC11594099

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Impact of Genetic Mutations on the Efficacy of Immunotherapies in Lung Cancer.PMID 39596025Read ↗

Research Progress in Immunotherapy of NSCLC With EGFR-Sensitive Mutations.Semantic proximity Read ↗

NSCLC: from tumorigenesis, immune checkpoint misuse to current and future targeted therapySemantic proximity Read ↗

Current Landscape of Targeted Therapy in Lung Cancer.Semantic proximity Read ↗

Targeted therapy for non-small-cell lung cancer: past, present and future.Semantic proximity Read ↗

Targeted Therapy and Immunotherapy for Lung Cancer.Semantic proximity Read ↗

[Research Progress in Immune Checkpoint Inhibitors Combination Therapy Applied to Non-small Cell Lung Cancer after EGFR Mutation-targeted Therapy Resistance].Semantic proximity Read ↗

Targeted therapies and immunotherapy in non-small-cell lung cancerSemantic proximity Read ↗

Novel therapeutic approaches for non-small cell lung cancer: an updated view.Semantic proximity Read ↗

Challenge and countermeasures for EGFR targeted therapy in non-small cell lung cancer.Semantic proximity Read ↗

Targeted therapy for lung cancer: Beyond EGFR and ALK.Semantic proximity Read ↗

Immunotherapy for Lung Malignancies: From Gene Sequencing to Novel Therapies.Semantic proximity Read ↗

Shaping the battlefield: EGFR and KRAS tumor mutations' role on the immune microenvironment and immunotherapy responses in lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.